Logout Lundbeck sites Contact Us

You are here: Front page » About Cipralex » Fast onset of action » Cipralex vs. venlafaxine XR
tip PRINT tip TIP A COLLEAGUE

Cipralex vs. venlafaxine XR

Earlier sustained remission with Cipralex

Patients in sustained remission (%)

Percentage of patients treated with escitalopram and venlafaxine xr 75–150 mg/day in sustained remission during an 8-week period. A larger proportion of escitalopram-treated patients achieved sustained remission at weeks 2–8 (logistic regression, including factors for treatment, centre and baseline MADRS score). Sustained remission was defined as patients in remission (MADRS≥12) that was maintained until week 8.
ITT; #p<0.05
##p<0.01

Patients in remission at week 8 (%)

Plot of number of patients in remission from each treatment group as a percentage of the total number of patients in remission at week 8. Escitalopram-treated patients achieving remission at week 8 achieved sustained remission 6.6 days faster than venlafaxine wr-treated patients. The dotted lines indicate median time to achieve remission.
ANCOVA, p<0.001

Cipralex works faster than venlafaxine XR

 

  • Cipralex offers earlier response and more patients achieved sustained remission in weeks 2-8 compared with venlafaxine XR.
  • Cipralex treated patients achieved 6,6 days earlier sustained remission than venlafaxine XR treated patients.
  • Furthermore Cipralex has a superior tolerability profile compared with venlafaxine XR and thus possesses a better benefit-risk profile.

References:

1. Montgomery et al. 2004

Published: 05/05/2006   Last updated: 27/07/2010
 
Key publication
Related key publications

www.irecover.com www.mypdinfo.com www.ebixa.com www.azilect.com www.serdolect.com www.depnet.com Disclaimer

H. Lundbeck A/S - Ottiliavej 9 - DK-2500 Copenhagen Valby - Phone +45 3630 1311 - Contact us

Lundbeck logo